Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

ClinicalTrials.gov ID: NCT03551522

Public ClinicalTrials.gov record NCT03551522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed due to the early termination of the study

Study identification

NCT ID
NCT03551522
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
181 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2018
Primary completion
May 7, 2019
Completion
Aug 9, 2020
Last update posted
Sep 14, 2022

2018 – 2020

United States locations

U.S. sites
14
U.S. states
6
U.S. cities
14
Facility City State ZIP Site status
CymaBay Research Site Glendale Arizona 85306
CymaBay Research Site Tucson Arizona 85712
CymaBay Research Site Los Angeles California 90057
CymaBay Research Site Boca Raton Florida 33434
CymaBay Research Site Lakewood Rch Florida 34211
CymaBay Research Site Flowood Mississippi 39232
CymaBay Research Site Clarksville Tennessee 37040
CymaBay Research Site Germantown Tennessee 38138
CymaBay Research Site Hermitage Tennessee 37076
CymaBay Research Site Knoxville Tennessee 37909
CymaBay Research Site Chandler Texas 85224
CymaBay Research Site Dallas Texas 75246
CymaBay Research Site Live Oak Texas 78233
CymaBay Research Site Rollingwood Texas 78746

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03551522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 14, 2022 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03551522 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →